Decision and Details
Advance disclosure document relating to the absorption-type company split
To transfer to the succeeding company the rights and obligations relating to the subject services among the nursing care businesses operated by the company effecting the split.
The company has determined that the performance of its obligations is expected to remain feasible. No specific amount of impact on financial results has been disclosed.
| Item | Details |
|---|---|
| Matter Covered | Advance disclosure document relating to the absorption-type company split |
| Decision Date | 12 May 2026 (date of execution of the absorption-type company split agreement) |
| Implementation Date | 1 July 2026 (scheduled; effective date) |
| Amount | Consideration for the split: none; increase in the capital and capital reserves of the succeeding company: none |
| Quantity / scale | Businesses involving the rights and obligations relating to CareWiz タクスト and CareWiz BCP |
| Impact on Business Performance | The company has determined that the performance of its obligations is expected to remain feasible. No specific amount of impact on financial results has been disclosed. |
| Reason | To transfer to the succeeding company the rights and obligations relating to the subject services among the nursing care businesses operated by the company effecting the split. |
| Governing Rule | Article 782, Paragraph 1 of the Companies Act; Article 794, Paragraph 1 of the Companies Act; Article 183 of the Ordinance for Enforcement of the Companies Act; Article 192 of the Ordinance for Enforcement of the Companies Act |
| Future plans | The absorption-type company split is scheduled to take effect on 1 July 2026. Any changes to these matters will be disclosed promptly. |
| Other disclosures | The company effecting the absorption-type company split is ExaWizards Inc., and the succeeding company is ExaMD Co., Ltd. The succeeding company is a wholly owned subsidiary. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to transfer the business covered by this disclosure to ExaMD Co., Ltd. and streamline the business operating structure. It has been explained that, after the split, the assets of both companies are expected to continue to substantially exceed their liabilities, and that the split is not expected to impede the performance of their obligations.